<DOC>
	<DOC>NCT02103257</DOC>
	<brief_summary>This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.</brief_summary>
	<brief_title>Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT) Patients must have previously untreated locally advanced or metastatic NSCLC EGFR activating mutation (exon 19 deletion, L858R) is required Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1 Prior chemotherapy or treatment with gefitinib, erlotinib, or other drugs that target EGFR Patients with wildtype EGFR Any other investigational agents are not permitted Any evidence of interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>